 | Up a level |
Journal Article
Brown, Jennifer R., Moslehi, Javid, O'Brien, Susan, Ghia, Paolo 
ORCID: 0000-0003-3750-7342, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Kipps, Thomas J., Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F., Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle and Burger, Jan A.
(2017).
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica, 102 (10).
S. 1796 - 1806.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078
O'Brien, Susan, Hillmen, Peter ORCID: 0000-0001-5617-4403, Coutre, Steven, Barr, Paul M., Fraser, Graeme, Tedeschi, Alessandra, Burger, Jan A., Dilhuydy, Marie-Sarah, Hess, Georg, Moreno, Carol, Cramer, Paula, Liu, Emily, Chang, Stephen, Vermeulen, Jessica, Styles, Lori, Howes, Angela, James, Danelle F., Patel, Kalpesh, Graef, Thorsten and Valentino, Rudolph
(2018).
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Clin. Lymphoma Myeloma Leuk., 18 (10).
S. 648 - 673.
DALLAS:
CIG MEDIA GROUP, LP.
ISSN 2152-2669
Younes, Anas, Sehn, Laurie H., Johnson, Peter ORCID: 0000-0003-2306-4974, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David ORCID: 0000-0002-4981-6188, Samoilova, Olga, Suh, Cheolwon, Leppae, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Cheung, Matthew C., Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duehrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S. Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham, Fisher, Richard I., Engert, Andreas, Stadtmauer, Edward A. and Wei, Lee-Jen
(2019).
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
J. Clin. Oncol., 37 (15).
S. 1285 - 1307.
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755